<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656484</url>
  </required_header>
  <id_info>
    <org_study_id>CCDI-UEFISCDI 39/2018</org_study_id>
    <nct_id>NCT03656484</nct_id>
  </id_info>
  <brief_title>New Periodontitis Treatment Based on Hyaluronic Acid and Melatonin</brief_title>
  <acronym>HAMELDENT</acronym>
  <official_title>Innovative Technology for Assessing the Periodontal Disease and New Periodontitis Treatment Based on Hyaluronic Acid and Melatonin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concordia Dent Srl</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carol Davila University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Romanian National Authority for Scientific Research and Innovation (UEFISCIDI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Politechnica of Bucharest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TURKEY MEDISEN Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Concordia Dent Srl</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to determine whether the association of Melatonin and
      Hyaluronic Acid to the antimicrobial TM paste (3% Tetracyclin and 3% Metronidazole) for
      periodontal maintenance therapy can improve the attachment level (AL) and alveolar bone
      support for moderate chronic periodontitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local drug delivery agents in periodontology has gained acceptance and popularity compared to
      systemic drugs due to decreased risk in development of resistant flora, opportunist
      infection, and side effects.

      In order to improve the topical treatment for chronic periodontitis, Melatonin and Hyaluronic
      Acid have been added to antimicrobial topic paste commercially available.

        -  A complex matrix composed of Tetracycline, Metronidazole, Melatonin and Hyaluronic Acid
           have been developed for local treatment of chronic periodontitis.

        -  Microbiological, physical, chemical characterization of the newly obtained matrix and
           biocompatibility tests have been performed.

        -  A randomized clinical trial will be perform on 50 patients with moderate chronic
           periodontitis recruited based on eligibility criteria and informed consent signed.

        -  Mechanical debridement of the pockets by scaling and root planning will be performed
           prior to the adjunctive therapy.

        -  Extensive clinical examination including charting the remaining teeth, clinical
           attachment level (CAL), presence of dental plaque (PI), gingival index (GI), calculus
           (CI), bleeding on probing (BOP), radiographic assessment and identification of
           periodontal pathogens with micro-IDent® test will be performed at the beginning of the
           study and 6 month after its completion.

        -  Each patient will be randomized using sealed envelopes (according to a
           computer-generated randomization list) to one of the following topical administration
           (in the periodontal pocket of affected teeth), for 30 consecutive days: Tetracycline and
           Metronidazole paste (TM), n=25 patients and Tetracycline, Metronidazole, Melatonin,
           Hyaluronic Acid paste (TM-MHa), n=25 patients.

        -  A statistical evaluation of data recorded during the entire follow-up period will be
           performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Clinical attachment level (CAL)</measure>
    <time_frame>before treatment (Baseline), at 6 months post treatment completion</time_frame>
    <description>Changes CAL from Baseline (before treatment) at 6 months will be assessed using a standardised protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Alveolar bone height</measure>
    <time_frame>before treatment (Baseline), at 6 months post treatment completion</time_frame>
    <description>Changes in the alveolar bone height from Baseline (before treatment) at 6 months will be assessed using standardised Radiographic measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment's influence on bactrial pathogens</measure>
    <time_frame>before treatment (Baseline), at 6 months post treatment completion</time_frame>
    <description>Periodontal pathogens will be identified by performing micro-IDent® assay before treatment (Baseline) and 6 month after its completion. Micro-IDent® test uses chain polymerisation reaction, with colorimetric detection, to identify the following pathogens: Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Bacteroides forsythus, Treponema denticola.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>Tetracycline-Metronidazole (TM) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3%Tetracycline and 3%Metronidazole paste (TM), n=25 patients, considered control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TM-Melatonin-Hyaluronic acid (TM-MHa) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3% Tetracycline, 3% Metronidazole, 0.18% Melatonin and 3% Hyaluronic Acid (TM-MHa) paste, n=25 patients, considered experimental group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline-Metronidazole (TM) group</intervention_name>
    <description>Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.</description>
    <arm_group_label>Tetracycline-Metronidazole (TM) group</arm_group_label>
    <other_name>TM group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TM-Melatonin-Hyaluronic acid (TM-MHa) group</intervention_name>
    <description>Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.</description>
    <arm_group_label>TM-Melatonin-Hyaluronic acid (TM-MHa) group</arm_group_label>
    <other_name>TM-MHa group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate chronic periodontitis, that is, &gt; 2 interproximal sites with AL &gt; 4 mm (not
             on the same tooth), or &gt; 2 interproximal sites with pocket depth (PD) &gt; 5 mm (not on
             the same tooth) (1),

          -  at least 20 teeth present in the mouth,

          -  no periodontal therapy during the last 6 months,

          -  no antibiotic during the last 6 months,

          -  good general health (no systemic condition affecting the course of periodontal
             disease, including malignancy), pregnancy,

          -  no allergy to the product components,

          -  good mental health.

        Exclusion Criteria:

          -  Patients not willing to sign consent form.

          -  Patients not agreeing with the treatment protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CORINA MARILENA CRISTACHE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carol Davila University of Medicine and Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Concordia Dent Clinic</name>
      <address>
        <city>Bucharest</city>
        <zip>041335</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Carol Davila&quot;University of Medicine and Pharmacy</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Eke PI, Page RC, Wei L, Thornton-Evans G, Genco RJ. Update of the case definitions for population-based surveillance of periodontitis. J Periodontol. 2012 Dec;83(12):1449-54. doi: 10.1902/jop.2012.110664. Epub 2012 Mar 16.</citation>
    <PMID>22420873</PMID>
  </reference>
  <reference>
    <citation>Feres M, Figueiredo LC, Soares GM, Faveri M. Systemic antibiotics in the treatment of periodontitis. Periodontol 2000. 2015 Feb;67(1):131-86. doi: 10.1111/prd.12075. Review.</citation>
    <PMID>25494600</PMID>
  </reference>
  <reference>
    <citation>Matesanz-Pérez P, García-Gargallo M, Figuero E, Bascones-Martínez A, Sanz M, Herrera D. A systematic review on the effects of local antimicrobials as adjuncts to subgingival debridement, compared with subgingival debridement alone, in the treatment of chronic periodontitis. J Clin Periodontol. 2013 Mar;40(3):227-41. doi: 10.1111/jcpe.12026. Epub 2013 Jan 16. Review.</citation>
    <PMID>23320860</PMID>
  </reference>
  <reference>
    <citation>Jepsen K, Jepsen S. Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis. Periodontol 2000. 2016 Jun;71(1):82-112. doi: 10.1111/prd.12121. Review.</citation>
    <PMID>27045432</PMID>
  </reference>
  <reference>
    <citation>Koyama H, Nakade O, Takada Y, Kaku T, Lau KH. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res. 2002 Jul;17(7):1219-29.</citation>
    <PMID>12096835</PMID>
  </reference>
  <reference>
    <citation>Montero J, López-Valverde N, Ferrera MJ, López-Valverde A. Changes in crevicular cytokines after application of melatonin in patients with periodontal disease. J Clin Exp Dent. 2017 Sep 1;9(9):e1081-e1087. doi: 10.4317/jced.53934. eCollection 2017 Sep.</citation>
    <PMID>29075409</PMID>
  </reference>
  <reference>
    <citation>Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. The Safety of Melatonin in Humans. Clin Drug Investig. 2016 Mar;36(3):169-75. doi: 10.1007/s40261-015-0368-5. Review.</citation>
    <PMID>26692007</PMID>
  </reference>
  <reference>
    <citation>Diker N, Gulsever S, Koroglu T, Yilmaz Akcay E, Oguz Y. Effects of Hyaluronic Acid and Hydroxyapatite/Beta-tricalcium Phosphate in Combination on Bone Regeneration of a Critical-size Defect in an Experimental Model. J Craniofac Surg. 2018 Jun;29(4):1087-1093. doi: 10.1097/SCS.0000000000004338.</citation>
    <PMID>29438204</PMID>
  </reference>
  <reference>
    <citation>Pirnazar P, Wolinsky L, Nachnani S, Haake S, Pilloni A, Bernard GW. Bacteriostatic effects of hyaluronic acid. J Periodontol. 1999 Apr;70(4):370-4.</citation>
    <PMID>10328647</PMID>
  </reference>
  <reference>
    <citation>Sakai A, Akifusa S, Itano N, Kimata K, Kawamura T, Koseki T, Takehara T, Nishihara T. Potential role of high molecular weight hyaluronan in the anti-Candida activity of human oral epithelial cells. Med Mycol. 2007 Feb;45(1):73-9.</citation>
    <PMID>17325947</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carol Davila University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Corina Marilena Cristache</investigator_full_name>
    <investigator_title>Senior Lecturer, DMD, PhD, Oral and Maxillofacial Surgeon, Project responsable</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Tetracycline</keyword>
  <keyword>Metronidazole</keyword>
  <keyword>topic paste</keyword>
  <keyword>chronic periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

